Innate Pharma (IDDA) Stock Overview
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IDDA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Innate Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.65 |
| 52 Week High | €1.67 |
| 52 Week Low | €1.65 |
| Beta | 0.51 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -54.67% |
| Change since IPO | -70.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDDA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.5% | 0.8% |
| 1Y | n/a | -30.8% | 13.6% |
Return vs Industry: Insufficient data to determine how IDDA performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how IDDA performed against the German Market.
Price Volatility
| IDDA volatility | |
|---|---|
| IDDA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IDDA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine IDDA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 174 | Jonathan Dickinson | www.innate-pharma.com |
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
Innate Pharma S.A. Fundamentals Summary
| IDDA fundamental statistics | |
|---|---|
| Market cap | €148.96m |
| Earnings (TTM) | -€46.05m |
| Revenue (TTM) | €12.64m |
Is IDDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDDA income statement (TTM) | |
|---|---|
| Revenue | €12.64m |
| Cost of Revenue | €43.42m |
| Gross Profit | -€30.79m |
| Other Expenses | €15.26m |
| Earnings | -€46.05m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Mar 26, 2026
| Earnings per share (EPS) | -0.50 |
| Gross Margin | -243.65% |
| Net Profit Margin | -364.44% |
| Debt/Equity Ratio | 513.5% |
How did IDDA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 13:56 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innate Pharma S.A. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Yigal Nochomovitz | Citigroup Inc |
| Michael Thomas Cooper | Edison Investment Research |